{"id":69946,"date":"2026-07-14T14:55:32","date_gmt":"2026-07-14T06:55:32","guid":{"rendered":"https:\/\/flcube.com\/?p=69946"},"modified":"2026-07-14T14:55:33","modified_gmt":"2026-07-14T06:55:33","slug":"huadong-medicines-subsidiary-secures-nmpa-approval-for-first-in-class-trispecific-agonist-dr10624-in-heart-failure-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69946","title":{"rendered":"Huadong Medicine&#8217;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that the clinical trial application for <strong>DR10624 injection<\/strong>, submitted by its subsidiary <strong>Zhejiang Doer Biotechnology Co., Ltd.<\/strong> (&#8220;Doer Bio&#8221;), has been approved by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>DR10624 injection \u2013 globally first-in-class long-acting trispecific agonist<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Adult HFpEF and HFrEF<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Zhejiang Doer Biotechnology Co., Ltd. (subsidiary of Huadong Medicine)<\/td><\/tr><tr><td><strong>Target Receptors<\/strong><\/td><td>FGF21R, GCGR, and GLP-1R<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-dr10624-triple-targeting-metabolic-modulator\" class=\"wp-block-heading\">DR10624 \u2013 Triple-Targeting Metabolic Modulator<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Long-acting trispecific agonist (first-in-class globally)<\/li>\n\n\n\n<li><strong>Targets:<\/strong><\/li>\n\n\n\n<li>Fibroblast growth factor 21 receptor (FGF21R) \u2013 metabolic regulation and anti-inflammatory effects<\/li>\n\n\n\n<li>Glucagon receptor (GCGR) \u2013 energy expenditure and glucose metabolism<\/li>\n\n\n\n<li>Glucagon-like peptide-1 receptor (GLP-1R) \u2013 insulin secretion and cardiovascular protection<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Independently developed by Doer Bio with global first-in-class designation<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Simultaneous activation of three complementary pathways addresses multiple pathophysiological mechanisms in heart failure<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-existing-clinical-development-pipeline\" class=\"wp-block-heading\">Existing Clinical Development Pipeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III:<\/strong> Severe hypertriglyceridemia (SHTG) \u2013 advanced stage development<\/li>\n\n\n\n<li><strong>Phase II:<\/strong> Metabolic dysfunction-associated steatotic liver disease\/MASH (MASLD\/MASH) \u2013 ongoing studies<\/li>\n\n\n\n<li><strong>New Indication:<\/strong> HFpEF\/HFrEF \u2013 newly approved for clinical trials<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Heart failure affects over 64 million people globally, with HFpEF representing approximately 50% of cases and historically limited treatment options compared to HFrEF.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-context\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Market Dynamics<\/th><\/tr><\/thead><tbody><tr><td><strong>Heart Failure Market<\/strong><\/td><td>Global market valued at $12+ billion, with HFpEF segment representing significant unmet need due to lack of effective therapies<\/td><\/tr><tr><td><strong>GLP-1 Class Competition<\/strong><\/td><td>Intense competition from semaglutide (Wegovy\/Ozempic), tirzepatide (Mounjaro\/Zepbound), but trispecific approach offers differentiated mechanism<\/td><\/tr><tr><td><strong>First-Mover Advantage<\/strong><\/td><td>As a first-in-class trispecific agonist, DR10624 could establish new standard of care if clinical data supports superior efficacy<\/td><\/tr><tr><td><strong>Metabolic-Cardiovascular Link<\/strong><\/td><td>Addresses growing recognition of metabolic dysfunction as key driver in heart failure pathogenesis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Success across multiple indications (SHTG, MASLD\/MASH, heart failure) validates Doer Bio&#8217;s trispecific platform technology<\/li>\n\n\n\n<li><strong>Commercial Synergies:<\/strong> Potential for combination pricing strategies across related metabolic-cardiovascular indications<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> First-in-class status creates opportunities for international partnerships or direct global development<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Triple mechanism of action provides potential advantages over mono- and dual-agonists in development by competitors<\/li>\n\n\n\n<li><strong>Investor Value Creation:<\/strong> Expansion into heart failure significantly increases peak sales potential beyond original metabolic disease focus<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The convergence of metabolic and cardiovascular therapeutics represents one of biopharma&#8217;s most promising growth areas, with multi-agonist approaches gaining significant investor and scientific interest.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory pathways, and commercial potential for DR10624. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a (1).\"><\/object><a id=\"wp-block-file--media-cae5e21b-6c60-42b5-8fbf-d987e565bbdb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a-1.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cae5e21b-6c60-42b5-8fbf-d987e565bbdb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,2508,114,887],"class_list":["post-69946","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-doer-biologics","tag-huadong-medicine","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine&#039;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (&quot;Doer Bio&quot;), has been approved by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine&#039;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (&quot;Doer Bio&quot;), has been approved by China&#039;s National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T06:55:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T06:55:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine&#8217;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment\",\"datePublished\":\"2026-07-14T06:55:32+00:00\",\"dateModified\":\"2026-07-14T06:55:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69946\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Doer Biologics\",\"Huadong Medicine\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69946#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69946\",\"name\":\"Huadong Medicine's Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T06:55:32+00:00\",\"dateModified\":\"2026-07-14T06:55:33+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (\\\"Doer Bio\\\"), has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69946\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine&#8217;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine's Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (\"Doer Bio\"), has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69946","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine's Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (\"Doer Bio\"), has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).","og_url":"https:\/\/flcube.com\/?p=69946","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T06:55:32+00:00","article_modified_time":"2026-07-14T06:55:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine&#8217;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment","datePublished":"2026-07-14T06:55:32+00:00","dateModified":"2026-07-14T06:55:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69946"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Doer Biologics","Huadong Medicine","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69946#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69946","url":"https:\/\/flcube.com\/?p=69946","name":"Huadong Medicine's Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T06:55:32+00:00","dateModified":"2026-07-14T06:55:33+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection, submitted by its subsidiary Zhejiang Doer Biotechnology Co., Ltd. (\"Doer Bio\"), has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69946"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine&#8217;s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69946\/revisions"}],"predecessor-version":[{"id":69948,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69946\/revisions\/69948"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}